SL
Therapeutic Areas
LivaNova Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VNS Therapy for TRD | Treatment-Resistant Depression | PMA Supplement |
| VNS Therapy for HF | Heart Failure (HFrEF) | Clinical Research |
| Next-Gen VNS Platform | Epilepsy & Depression | Development |
| Essenz Next-Gen | Cardiopulmonary Surgery | Development |
Leadership Team at LivaNova
WA
William A. Kozy
Interim Chief Executive Officer and Chairman of the Board
AS
Alex Shvartsburg
Interim Chief Financial Officer
JH
Jonathan Hunt
Chief Commercial Officer
EA
Edward Andrle
SVP, General Counsel, and Corporate Secretary
JC
Juan Carlos Ibarra
SVP, R&D, Neuromodulation
AL
Alfredo L. Arnaud
SVP, R&D, Cardiopulmonary